tislelizumab
beigene,novartis
 tislelizumab survival for untreated advanced squamous oesophageal cancer rationale-306 results at #wcgic2022 os by &gt; 6m in pd-l1 cps&gt;10 and all comers benefit in pd-l1 negative (not shown) mixed chemo backbones (+oxali &amp; 5fu free) more options for patients 
Medical Oncologist.  Cancer Researcher. ???? in ???? ?? ??????.  Always falling over and getting back up again.